Keywords: GlaxoSmithKline, UK investment in manufacturing, Tax, FDA breifing, Avodart, Merck & Co, Proscar

GlaxoSmithKline to invest £500 million in UK after tax promise; faces questions on Avodart benefits

Article | 30 November 2010

Print This

As a result government tax pledges, UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) plans to invest £500 million ($780.6 million) in new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in